Feasibility of teledermatology in the eradication of leishmaniasis from Yemen project
Global Dermatology · 2017 · 4 (2)
DOI: 10.15761/god.1000206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Dermatology, 2017. Verfasst von Mohamed Ahmed Al-Kamel. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
that predominantly prevail among poor rural children and women, Regional Leishmaniasis Control Center (RLCC) was founded during April 2013 as a first phase of the project ELYP.Immediately, as the second phase of the project ELYP, RLCC released several integrated programs for the same purpose.Because of the complex geography of Yemen, weak infrastructures, scarce medical facilities in rural areas, deteriorating economic status, high cost of health care, conflicts and instability, Teledermatology program was adopted as a standalone innovative program that may provide a communication tool between caregiver each other at different regional centers/units, them and their instructors and project supporters abroad and between leishmaniasis patients in distant disadvantaged areas and their treating doctors at center's regional clinics [2-4]. RLCC's teledermatology program resourcesDue to scarcity in resources, RLCC has not relied on specific telemedicine-specific hardware or software to implement teledermatology program, but it utilized all available resources as to support the program.
Zitieren
APA
Al-Kamel, M. A. (2017). Feasibility of teledermatology in the eradication of leishmaniasis from Yemen project. Global Dermatology, 4(2). https://doi.org/10.15761/god.1000206
Vancouver
Al-Kamel MA. Feasibility of teledermatology in the eradication of leishmaniasis from Yemen project. Global Dermatology. 2017;4(2). doi:10.15761/god.1000206
BibTeX
@article{AlKamel2017,
author = {Al-Kamel, Mohamed Ahmed},
title = {Feasibility of teledermatology in the eradication of leishmaniasis from Yemen project},
journal = {Global Dermatology},
year = {2017},
volume = {4},
number = {2},
doi = {10.15761/god.1000206}
}
EUVIMED